Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1995-9-5
|
| pubmed:abstractText |
Carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and CA125 were determined pre- and postoperatively in non-small cell lung cancer patients (NSCLC) to assess the relationship between serum levels and postoperative recurrent disease. Ninety-five patients who underwent curative surgical resection were included (TNM stages I, II, IIIa). CEA and CA125 were determined by solid-phase enzyme-immunoassay, SCC by radio-immunoassay. Tumor relapse was detected in 41 patients (43%): 16 (39%) with locoregional disease and 25 (61%) with disseminated disease. The overall 36-month disease-free survival rate was 42%. The sensitivity for recurrence was 58% for CEA, 53.6% for CA125, and 51.2% for SCC; 87.8% of patients showed at least one elevated marker. The sensitivity of CEA and CA125 increased significantly in patients with preoperative serum concentrations above the cut-off: 86.6% versus 42.3% (p < 0.01), and 93% versus 18% (p < 0.01), respectively. Preoperative CA125 above 15 U/ml identified a high-risk group of patients: a lower 36-month disease-free survival rate (0% versus 56%) (p < 0.001), a 3.02-fold higher risk of recurrence (p < 0.05), and a 6.22-fold higher risk of disseminated failure (p < 0.001). The identification of CEA and CA125 producer-tumors, based on preoperative serum values, enhances the clinical performance of a postoperative surveillance program in surgically treated NSCLC. Preoperative serum CA125 is a prognostic factor to identify patients at high risk of postoperative tumor recurrence.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/CA-125 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Carcinoembryonic Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Serpins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/squamous cell carcinoma-related...
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0393-6155
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5-10
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7629428-Aged,
pubmed-meshheading:7629428-Antigens, Neoplasm,
pubmed-meshheading:7629428-CA-125 Antigen,
pubmed-meshheading:7629428-Carcinoembryonic Antigen,
pubmed-meshheading:7629428-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:7629428-Disease-Free Survival,
pubmed-meshheading:7629428-Female,
pubmed-meshheading:7629428-Follow-Up Studies,
pubmed-meshheading:7629428-Humans,
pubmed-meshheading:7629428-Lung Neoplasms,
pubmed-meshheading:7629428-Male,
pubmed-meshheading:7629428-Middle Aged,
pubmed-meshheading:7629428-Neoplasm Metastasis,
pubmed-meshheading:7629428-Neoplasm Recurrence, Local,
pubmed-meshheading:7629428-Risk Factors,
pubmed-meshheading:7629428-Sensitivity and Specificity,
pubmed-meshheading:7629428-Serpins,
pubmed-meshheading:7629428-Treatment Failure,
pubmed-meshheading:7629428-Tumor Markers, Biological
|
| pubmed:articleTitle |
Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non-small cell lung cancer.
|
| pubmed:affiliation |
Hospital Universitario, Alcalá de Henares, Madrid, Spain.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|